Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update

BACKGROUND: The randomised phase 2 CABOSUN trial comparing cabozantinib with sunitinib as initial therapy for advanced renal cell carcinoma (RCC) of intermediate or poor risk met the primary end-point of improving progression-free survival (PFS) as assessed by investigator. We report PFS by independ...

Descripción completa

Detalles Bibliográficos
Autores principales: Choueiri, Toni K., Hessel, Colin, Halabi, Susan, Sanford, Ben, Michaelson, M. Dror, Hahn, Olwen, Walsh, Meghara, Olencki, Thomas, Picus, Joel, Small, Eric J., Dakhil, Shaker, Feldman, Darren R., Mangeshkar, Milan, Scheffold, Christian, George, Daniel, Morris, Michael J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057479/
https://www.ncbi.nlm.nih.gov/pubmed/29550566
http://dx.doi.org/10.1016/j.ejca.2018.02.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057479/
https://www.ncbi.nlm.nih.gov/pubmed/29550566
http://dx.doi.org/10.1016/j.ejca.2018.02.012

Ejemplares similares